Nebivolol +pharma (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol +pharma, is a beta blocker presented as an oral tablet for oral use. It treats hypertension and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Nebivolol +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

Hypertension: lowers blood pressure by reducing heart rate and peripheral resistance. Heart failure (reduced ejection fraction): improves cardiac output and symptoms by enhancing ventricular filling and decreasing afterload. Left ventricular dysfunction: supports ventricular performance through vasodilation and heart‑rate control.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nausea or gastrointestinal discomfort. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to fainting. - Acute heart failure decompensation. - Bronchospasm in patients with reactive airway disease. - Allergic skin reactions such as rash or urticaria.

Nebivolol requires careful assessment before and during therapy.

Monitor blood pressure: ensure target levels are achieved without excessive drop. Assess cardiac function: especially in patients with existing heart failure. Use caution in asthma or chronic obstructive pulmonary disease: β‑blockade may exacerbate bronchospasm. Adjust dose in renal impairment: clearance may be reduced. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other β‑blockers: additive negative chronotropic effects. - Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): risk of severe bradycardia. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect. - ACE inhibitors or ARBs: enhanced blood‑pressure lowering. - NSAIDs: may blunt antihypertensive response. - Anti‑arrhythmic agents (e.g., amiodarone): possible conduction disturbances.